Matrix Metalloproteinases as Targets for Prostate Cancer Bone Metastasis
Author Information
Author(s): Bonfil R.D., Fridman R., Mobashery S., Cher M.L.
Primary Institution: Wayne State University School of Medicine
Hypothesis
Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?
Conclusion
Matrix metalloproteinases play a significant role in the progression of prostate cancer bone metastasis and may serve as potential therapeutic targets.
Supporting Evidence
- MMPs are involved in the normal turnover of extracellular matrix and bone remodeling.
- Inhibition of MMPs has been shown to reduce tumor growth and bone degradation in experimental models.
- High expression of MMP-2 and MMP-9 was confirmed in prostate cancer cells and surrounding bone stromal cells.
Takeaway
This study looks at how certain proteins called matrix metalloproteinases help prostate cancer spread to bones, and suggests that blocking these proteins might help treat the cancer.
Methodology
The study involved experimental models using human prostate cancer cells in human bone xenografts to assess the role of matrix metalloproteinases in bone metastasis.
Limitations
The study primarily relies on animal models, and clinical trials in humans have not yet been conducted to evaluate the efficacy of MMP inhibitors.
Want to read the original?
Access the complete publication on the publisher's website